11 – 20 of 37
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2018
-
Mark
Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second-line lenalidomide + dexamethasone induction in multiple myeloma
(
- Contribution to journal › Article
- 2017
-
Mark
Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma Register
(
- Contribution to journal › Article
-
Mark
Direct evidence for a polygenic etiology in familial multiple myeloma
(
- Contribution to journal › Article
- 2016
-
Mark
Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma.
(
- Contribution to journal › Article
-
Mark
Genome-wide association study identifies multiple susceptibility loci for multiple myeloma
(
- Contribution to journal › Article
- 2015
-
Mark
Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients.
(
- Contribution to journal › Article
-
Mark
Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma.
(
- Contribution to journal › Article
- 2013
-
Mark
Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial
(
- Contribution to journal › Article
- 2012
-
Mark
Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study
(
- Contribution to journal › Article
- 2011
-
Mark
Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study
(
- Contribution to journal › Article